Clinical Report: Assessment of Surgical Interventions in LS-SCLC
Overview
Expand on the implications of advanced pTNM stage and postoperative brain metastasis.
Background
Small cell lung cancer (SCLC) is a highly aggressive malignancy with a poor prognosis, particularly in limited-stage disease. The role of surgery in LS-SCLC remains debated, as traditional treatment has focused on chemoradiotherapy. Understanding the potential benefits of surgical intervention could optimize treatment strategies and improve patient outcomes.
Data Highlights
Measure
Median
5-Year Rate
Overall Survival (OS)
81 months
58.3%
Disease-Free Survival (DFS)
50 months
50.5%
Stage I-IIA OS
-
69.2%
Stage IIB-IIIB OS
-
47.1%
Key Findings
Median overall survival (OS) for patients was 81 months with a 5-year OS rate of 58.3%.
Patients with stage I-IIA disease had significantly better survival outcomes compared to those with stage IIB-IIIB (5-year OS: 69.2% vs. 47.1%, P = 0.017).
Advanced pathological Tumor-Node-Metastasis (pTNM) stage was identified as an independent adverse prognostic factor (HR = 1.848, P = 0.010).
Adjuvant chemotherapy plus thoracic radiotherapy was associated with improved survival outcomes.
Postoperative brain metastasis significantly worsened outcomes, with a 5-year OS of 21.9% compared to 74.6% without it (P < 0.001).
Clinical Implications
The findings suggest that radical surgery followed by adjuvant therapy can improve survival in selected LS-SCLC patients, particularly those with earlier-stage disease. Clinicians should consider integrating surgical options into treatment plans for appropriately staged patients.
Conclusion
This retrospective analysis highlights the potential benefits of surgical intervention in LS-SCLC, warranting further prospective studies to validate these findings. The identification of prognostic factors can aid in tailoring treatment strategies for improved patient outcomes.
